Manejo farmacológico do distúrbio mineral-ósseo da doença renal crônica - uma revisão integrativa
DOI:
https://doi.org/10.11606/issn.1679-9836.v104i5e-229210Palavras-chave:
Tratamento, Osteodistrofia renal, Distúrbio mineral-ósseo da doença renal crônicaResumo
Introdução: O distúrbio mineral-ósseo da doença renal crônica é uma condição sistêmica caracterizada por anormalidades no metabolismo de minerais como o cálcio e fósforo, de hormônios como o paratormônio e o fator de crescimento fibroblástico-23 (FGF-23), da vitamina D e do osso em si, resultando no aumento de morbidade e mortalidade dos pacientes acometidos, cuja compreensão de sua fisiopatologia e manejo tem evoluído nos últimos anos. Objetivo: Estabelecer as recomendações e evidências atuais do manejo farmacológico do distúrbio mineral-ósseo da doença renal crônica. Métodos e Resultados: O artigo consiste em uma revisão integrativa da literatura utilizando como fonte bibliográfica estudos da base de dados do Pubmed, da BVS (Biblioteca Virtual de Saúde) - Medline/Lilacs e do UpToDate, sendo ainda complementado pelas últimas recomendações oficiais sobre o tema da Kidney Disease: Improving Global Outcomes (KDIGO) de 2017. Discussão e Conclusão: O tratamento farmacológico do distúrbio-mineral ósseo da doença renal crônica consiste no manejo da hiperfosfatemia, do hiperparatireoidismo secundário e do controle dos níveis de cálcio e vitamina D, que, à despeito de certas divergências na literatura quanto à eficácia no desfecho de mortalidade do paciente, resultam atualmente na geração de melhor qualidade de vida para os pacientes.
Downloads
Referências
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-53. Doi: 10.1038/sj.ki.5000414.
Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18(6):1637-47. Doi: 10.1681/ASN.2007010068.
Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens. 2007;16(4):329-35. Doi: 10.1097/MNH.0b013e3281ca6ffd.
Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65(5):1943-6. Doi: 10.1111/j.1523-1755.2004.00604.x.
Martin KJ, González EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol. 2007;18(3):875-85. Doi: 10.1681/ASN.2006070771.
Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. Doi: 10.1038/sj.ki.5002009.
Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest. 1995;96(4):1786-93. Doi: 10.1172/JCI118224.
KDIGO Work Group 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. Doi: 10.1016/j.kisu.2017.04.001.
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;22(8). Doi: 10.1002/14651858.CD006023.pub3.
Greeviroj P, Kitrungphaiboon T, Katavetin P, Praditpornsilpa K, Eiam-Ong S, Jaber BL et al. Cinacalcet for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: A Meta-Analysis of Randomized Controlled Trials. Nephron. 2018;139(3):197-210. Doi: 10.1159/000487546.
Zhao L, Liu A, Xu G. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patientes: a meta-analysis. Ren Fail. 2021;43(1):1378-93. Doi: 10.1080/0886022X.2021.1986068.
Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S et al. Effects of 12 months of recombinant growth hormone therapy on parameteres of boné metabolismo and bone mineral density in patients on chronic hemodialysis. J Nephrol. 2004;17(1):87-94. PMID: 15151263.
Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V et al. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disese-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019;34(7):1163-70. Doi: 10.1093/ndt/gfy127.
Zhang D, Li H, Yin D, Wang L, Mao Y. Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: a randomized controlled trial. Eur J Pharmacol. 2016:789:127-33. Doi: 10.1016/j.ejphar.2016.07.019.
D'Haese PC, Spasovski GB, Sikole A, Hutchsion A, Freemont TJ, Sulkova S et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003:(85):S73-8. Doi: 10.1046/j.1523-1755.63.s85.18.x.
Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19(2):405-12. Doi: 10.1681/ASN.2006101089.
Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310(6976):358-63. Doi: 10.1136/bmj.310.6976.358.
Patel L, Bernard LM, Elder GJ. Sevelamer versus calcium-based phosphate biners for chronic kidney disease. Clin J Am Soc Nephrol. 2016;11(2):232-44. Doi: 10.2215/CJN.06800615.
Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone and increasing fibroblast growth-factor 23 in secondary hyperparathyroidism. Kidney Int. 2011;79(1):112-9. Doi: 10.1038/ki.2010.352.
Webb NJA, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G et al. Efficacy and safety of paricalcitol in children with stage 3 to 5 chronic kidney disease. Pediatr Nephrol. 2017;32(7):1221-32. Doi: 10.1007/s00467-017-3579-6..
Sekercioglu N, Thabane L, Martínez JPD, Nesrallah G, Longo CJ, Busse JW et al. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS One. 2016;11(6):e0156891. Doi: 10.1371/journal.pone.0156891.
Tsujita M, Doi Y, Obi Y, Hamano T, Tomosugi T, Futamura K et al. Cholecalciferol Supplementation Attenuates Bone Loss in Incident Kidney Transplant Recipients: A Prespecified Secondary Endpoint Analysis of a Randomized Controlled Trial. J Bone Miner Res. 2022;37(2):303-11. Doi: 10.1002/jbmr.4469.
Massart A, Debelle FD, Racapé J, Gervy C, Husson C, Dhaene M et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Am J Kidney Dis. 2014;64(5):696-705. Doi: 10.1053/j.ajkd.2014.04.020.
Malhotra R, Katz R, Hoofnagle A, Bostom A, Rifkin DE, Mcbride R et al. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD. Clin J Am Soc Nephrol. 2018;13(1):36-44. Doi: 10.2215/CJN.05440517
Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?. Semin Dial. 2003;16(3):186-8. Doi: 10.1046/j.1525-139x.2003.16037.x.
Mc Govern AP, De Lusignan S, Van Vlymen J, Liyanage H, Tomson CR, Gallagher H et al. Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study. PLoS One. 2013;8(9): e74996. Doi: 10.1371/journal.pone.0074996.
Lynch KE, Lynch R, Curhan GC, Brunelli SM. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(3):620-9. Doi: 10.2215/CJN.04620510.
Luo H, Feng J, Xue G, Zhang Y, Li Y, Huang X et al. Comparative Efficacy and Acceptability of 12 Phosphorus-Lowering Drugs in Adults with Hyperphosphatemia and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. Blood Purif. 2023;52(7-8):609-620. Doi: 10.1159/000531577.
Iorio BD, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D et al. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771-8. Doi: 10.1053/j.ajkd.2013.03.023.
Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483-90. Doi: 10.1046/j.1523-1755.2003.00878.x.
Zhang T, Ju H, Chen H, Wen W. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. Ther Apher Dial. 2019;23(1):73-79. Doi: 10.1111/1744-9987.12760.
Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis. 2020;76(3):321-30. Doi: 10.1053/j.ajkd.2020.02.4.
Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG et al. EVOLVE Trial: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482-94. Doi: 10.1056/NEJMoa1205624.
Bernardor J, De Mul A, Bacchetta J, Schmitt CP. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Curr Osteoporos Rep. 2023;21(2):193-204. Doi: 10.1007/s11914-023-00782-x.
Tang JA, Friedman J, Hwang MS, Salapatas AM, Bonzelaar LB, Friedman M. Parathyroidectomy for tertiary hyperparathyroidism: A systematic review. Am J Otolaryngol. 2017;38(5):630-5. Doi: 10.1016/j.amjoto.2017.06.009.
Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara T, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;88(2):350-9. Doi: 10.1038/ki.2015.72.
Floege J, Kim J, Ireland E, Chazot C, Drueke T, De Francisco A et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948-55. Doi: 10.1093/ndt/gfq219.
Fukagawa M, Kido R, Komaba H, Onishi Y, Yamaguchi T, Hasegawa T et al. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Am J Kidney Dis. 2014;63(6):979-87. Doi: 10.1053/j.ajkd.2013.08.011.
Kandula P, Dobre M, Schold JD, Schreiber Jr MJ, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6(1):50-62. Doi: 10.2215/CJN.03940510.
Guo G, Zhou J, Xu T, Sheng Z, Huang A, Sun L et al. Effect of Magnesium Supplementation on Chronic Kidney Disease-Mineral and Bone Disorder in Hemodialysis Patients: A Meta-Analysis of Randomized Controlled Trials. J Ren Nutr. 2022;32(1):102-11. Doi: 10.1053/j.jrn.2021.07.00.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Matheus Noronha Alberti
Este trabalho está licenciado sob uma licença Creative Commons Attribution-ShareAlike 4.0 International License.
